Clinical Trials Logo

Clinical Trial Summary

The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03276910
Study type Interventional
Source Association Athletes For Transparency
Contact Pierre SALLET, phD
Phone +33661587265
Email p.sallet@athletesfortransparency.com
Status Not yet recruiting
Phase Phase 1
Start date September 8, 2017
Completion date June 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT03028532 - Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting Phase 1
Active, not recruiting NCT04965961 - The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females N/A
Withdrawn NCT04402658 - Can Anti-asthmatic Medication Improve Sprint Performance in Healthy Endurance Athletes? N/A